Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
47.40B
Market cap47.40B
Price-Earnings ratio
1.50K
Price-Earnings ratio1.50K
Dividend yield
Dividend yield
Average volume
1.68M
Average volume1.68M
High today
$368.07
High today$368.07
Low today
$358.59
Low today$358.59
Open price
$361.55
Open price$361.55
Volume
422.44K
Volume422.44K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 47.4B, Alnylam Pharmaceuticals(ALNY) trades at $358.81. The stock has a price-to-earnings ratio of 1503.12.

As of 2026-01-27, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $358.59 and $368.07. The current price stands at $358.81, placing the stock +0.1% above today's low and -2.5% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 422.44K, compared to an average daily volume of 1.68M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 5d
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals Investors?

Earlier in January 2026, Alnylam Pharmaceuticals issued full-year 2026 guidance, projecting combined net product revenue of US$4.90 billion to US$5.30 billion,...

Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals Investors?

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.